GlobeNewswire

Tenaris Announces 2018 First Quarter Results

Dela

Tenaris S.A. / Tenaris Announces 2018 First Quarter Results . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standard Board ("IASB") and in conformity with IFRS as adopted by the European Union ("EU"). Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Net cash / debt and Free Cash Flow. See exhibit I for more details on these alternative performance measures.

LUXEMBOURG, April 26, 2018 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE:TS) (BAE:TS) (BMV:TS) (MILAN:TEN) ("Tenaris") today announced its results for the quarter ended March 31, 2018 in comparison with its results for the quarter ended March 31, 2017.

Summary of 2018 First Quarter Results

(Comparison with fourth and first quarter of 2017)

  1Q 2018 4Q 2017 1Q 2017
Net sales ($ million) 1,866   1,589   17 % 1,154   62 %
Operating income ($ million) 212   168   26 % 36   489 %
Net income ($ million) 235   162   45 % 206   14 %
Shareholders' net income ($ million) 235   160   47 % 205   15 %
Earnings per ADS ($) 0.40   0.27   47 % 0.35   15 %
Earnings per share ($) 0.20   0.14   47 % 0.17   15 %
EBITDA ($ million) 354   319   11 %   198   79 %
EBITDA margin (% of net sales) 19.0 % 20.1 %   17.2 %  

In the first quarter of 2018, sales, which rose 17% quarter on quarter and 62% year on year, were boosted by an exceptional level of shipments for East Mediterranean pipelines and a high level of sales during the peak Canadian drilling season. Earnings per share, operating income and EBITDA continue to recover and benefit from higher absorption of fixed costs although the EBITDA margin was affected by higher raw material costs and lower margins on the East Mediterranean shipments. 

During the quarter, we had a further increase of working capital of $364 million, reflecting an increase in receivables associated with a high level of sales towards the end of the quarter. Net cash flow used in operations amounted to $30 million. After capital expenditures of $92 million, our net cash position declined to $557 million at the end of the quarter.

Market Background and Outlook

In the year to date, shale drilling activity in the USA has grown steadily while, in Canada, growth is being affected by takeaway capacity constraints and wider commodity price spreads. In the rest of the world, higher oil prices are leading to a gradual recovery in onshore drilling activity. In Latin America, despite promising results from the reform programs in Brazil and Mexico and further interest in the Vaca Muerta shale play in Argentina, drilling activity has been slow to pick up outside Colombia and the new deepwater play in Guyana.

The full extent of US Section 232 tariffs on steel imports is still unclear but as far as imports of steel pipes are reduced by quotas or the application of the 25% tariff, Tenaris expects to be well placed to increase production at its US domestic facilities.

In the coming quarters, we expect shipments to be lower than the first quarter but sales and margins should benefit from price increases that compensate recent increases in raw material costs. EBITDA and operating income should continue to show growth through the year.

Analysis of 2018 First Quarter Results

Tubes Sales volume (thousand metric tons) 1Q 2018 4Q 2017 1Q 2017
Seamless   651   593 10 %   509 28 %
Welded   285   171 67 %   74 283 %
Total   936   764 23 %   583 61 %

 

Tubes 1Q 2018 4Q 2017 1Q 2017
(Net sales - $ million)          
North America 807   707   14 % 477   69 %
South America 285   296   (4 %) 203   40 %
Europe 153   133   15 % 130   17 %
Middle East & Africa 456   290   57 % 230   98 %
Asia Pacific 66   51   29 % 46   45 %
Total net sales ($ million) 1,766   1,478   20 % 1,085   63 %
Operating income ($ million) 194   150   29 % 31   524 %
Operating margin (% of sales) 11.0 % 10.1 %   2.8 %  

Net sales of tubular products and services increased 20% sequentially and 63% year on year. In North America sales increased 14% sequentially, reflecting high sales in Canada in the peak drilling season and higher sales in the United States onshore. In South America sales declined 4% sequentially, as slightly higher sales of OCTG in Argentina were offset by lower sales elsewhere. In Europe sales increased 15% thanks to an increase in demand for mechanical pipe and line pipe for power generation and hydrocarbon processing industry. In the Middle East and Africa sales increased 57%, boosted by an exceptional level of shipments of line pipe products for the Zohr project in the East Mediterranean and stable sales elsewhere. In Asia Pacific sales increased 29% thanks to higher shipments throughout the region and particularly in Thailand.

Operating income from tubular products and services amounted to $194 million in the first quarter of 2018, compared to $150 million in the previous quarter and $31 million in the first quarter of 2017. The sequential increase is a result of an improvement in the margin on higher sales. While during the quarter average selling prices declined 2% (reflecting a mix of products with higher participation of welded line pipe products) and costs of sales remained stable (higher direct cost of sales offset by a positive volume effect on fixed costs), the operating margin improved following the reduction of selling, general and administrative expenses as a percentage of sales.

Others 1Q 2018 4Q 2017 1Q 2017
Net sales ($ million) 100   111   (10 %) 68   46 %
Operating income ($ million) 19   18   2 %   5   246 %
Operating income (% of sales) 18.7 % 16.5 %   7.9 %  

Net sales of other products and services decreased 10% sequentially but increased 46% year on year. The sequential decrease in sales is mainly related to lower sales of sucker rods.

Selling, general and administrative expenses, or SG&A, amounted to $350 million, or 18.7% of net sales, in the first quarter of 2018, compared to $344 million, 21.6% in the previous quarter and $294 million, 25.5% in the first quarter of 2017. Sequentially, SG&A declined as a percentage of sales due to a better absorption of fixed costs on higher sales and lower provisions for contingencies and doubtful accounts and the termination of the amortization of intangible assets of our Canadian subsidiary for $13 million.

Financial results amounted to a loss of $8 million in the first quarter of 2018, compared to a gain of $4 million in the previous quarter and a loss of $4 million in the first quarter of 2017. The loss of the quarter is mainly explained by lower interest results on a lower net cash position and a foreign exchange loss, net of derivatives results, of $7 million, mainly related to the negative impact from Euro appreciation against the U.S. dollar on Euro denominated intercompany liabilities in subsidiaries with functional currency U.S. dollar. The net foreign exchange loss is to a large extent offset in equity, in the currency translation adjustment reserve.

Equity in earnings of  non-consolidated  companies generated a gain of $46 million in the first quarter of 2018, compared to a gain of $26 million in the previous quarter and a gain of $35 million in the first quarter of 2017. These results are mainly derived from our equity investment in Ternium  (NYSE:TX) and Usiminas (BSP:USIM).

Income tax  charge amounted to $15 million in the first quarter of 2018, positively affected by currency movements on the tax base used to calculate deferred taxes at our subsidiaries which have the U.S. dollar as their functional currency for $20 million. This compares to an income tax charge of $36 million in the previous quarter and an income tax gain of $47 million in the first quarter of last year positively affected by the effect of the Mexican and Argentine peso revaluation on the tax base used to calculate deferred taxes at our Mexican and Argentine subsidiaries which have the U.S. dollar as their functional currency.

Cash Flow and Liquidity

Net cash used in operations during the first quarter of 2018 was $30 million as we had a further increase of working capital of $364 million, reflecting an increase in receivables associated with a high level of sales towards the end of the quarter, compared to a cash generation of $26 million in the first quarter of 2017 and $13 million used in the previous quarter.

Capital expenditures amounted to $92 million for the first quarter of 2018, compared to $121 million in the previous quarter and $139 million in the first quarter of 2017.

At the end of the quarter, our net cash position amounted to $557 million, compared to $680 million at the beginning of the year.

Conference call

Tenaris will hold a conference call to discuss the above reported results, on April 27, 2018, at 08:00 a.m. (Eastern Time). Following a brief summary, the conference call will be opened to questions. To access the conference call dial in +1 877 730 0732 within North America or +1 530 379.4676 Internationally. The access number is "4878327". Please dial in 10 minutes before the scheduled start time. The conference call will be also available by webcast at www.tenaris.com/investors.

A replay of the conference call will be available on our webpage http://ir.tenaris.com/ or by phone from 12.00 pm ET on April 27th, through 10.59 pm on May 6th, 2018. To access the replay by phone, please dial 855 859 2056 or 404 537 3406 and enter passcode "4878327" when prompted.

Some of the statements contained in this press release are "forward-looking statements". Forward-looking statements are based on management's current views and assumptions and involve known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied by those statements. These risks include but are not limited to risks arising from uncertainties as to future oil and gas prices and their impact on investment programs by oil and gas companies.

Consolidated Condensed Interim Income Statement

(all amounts in thousands of U.S. dollars) Three-month period ended March 31,
  2018   2017  
Continuing operations Unaudited
Net sales 1,866,235   1,153,860  
Cost of sales (1,305,506 ) (823,856 )
Gross profit 560,729   330,004  
Selling, general and administrative expenses (349,634 ) (294,431 )
Other operating income (expense), net 1,102   441  
Operating income 212,197   36,014  
Finance Income 9,373   12,927  
Finance Cost (10,174 ) (5,938 )
Other financial results (7,066 ) (11,415 )
Income before equity in earnings of non-consolidated companies and income tax 204,330   31,588  
Equity in earnings of non-consolidated companies 46,026   35,200  
Income before income tax 250,356   66,788  
Income tax (15,122 ) 47,245  
Income for continuing operations 235,234   114,033  
     
Discontinued operations    
Result for discontinued operations  -    91,542  
Income for the period 235,234   205,575  
     
Attributable to:    
Owners of the parent 234,983   205,127  
Non-controlling interests 251   448  
  235,234   205,575  
 

Consolidated Condensed Interim Statement of Financial Position

(all amounts in thousands of U.S. dollars) At March 31, 2018   At December 31, 2017
  Unaudited    
ASSETS          
Non-current assets          
  Property, plant and equipment, net 6,218,278     6,229,143  
  Intangible assets, net 1,635,785     1,660,859  
  Investments in non-consolidated companies 681,323     640,294  
  Available for sale assets 21,572     21,572  
  Other investments 239,600     128,335  
  Deferred tax assets 169,926     153,532  
  Receivables, net 173,446 9,139,930   183,329 9,017,064
Current assets          
  Inventories, net 2,384,411     2,368,304  
  Receivables and prepayments, net 177,050     143,929  
  Current tax assets 139,506     132,334  
  Trade receivables, net 1,554,949     1,214,060  
  Other investments 999,576     1,192,306  
  Cash and cash equivalents 328,675 5,584,167   330,221 5,381,154
Total assets   14,724,097     14,398,218
EQUITY           
Capital and reserves attributable to owners of the parent   11,750,621     11,482,185
Non-controlling interests   99,191     98,785
Total equity   11,849,812     11,580,970
LIABILITIES          
Non-current liabilities          
  Borrowings 34,948     34,645  
  Deferred tax liabilities 413,135     457,970  
  Other liabilities 220,085     217,296  
  Provisions 39,031 707,199   36,438 746,349
Current liabilities          
  Borrowings 970,647     931,214  
  Current tax liabilities 108,847     102,405  
  Other liabilities 208,645     197,504  
  Provisions 31,264     32,330  
  Customer advances 37,424     56,707  
  Trade payables 810,259 2,167,086   750,739 2,070,899
Total liabilities   2,874,285     2,817,248
Total equity and liabilities   14,724,097     14,398,218
 

Consolidated Condensed Interim Statement of Cash Flows

    Three-month period ended March 31,
(all amounts in thousands of U.S. dollars)   2018   2017  
Cash flows from operating activities   Unaudited
       
Income for the period   235,234   205,575  
Adjustments for:        
Depreciation and amortization   141,802   162,218  
Income tax accruals less payments   (24,816 ) (92,930 )
Equity in earnings of non-consolidated companies   (46,026 ) (35,200 )
Interest accruals less payments, net   620   (2,460 )
Changes in provisions   1,527   (17,838 )
Income from the sale of Conduit business    -    (89,694 )
Changes in working capital   (363,552 ) (104,937 )
Currency translation adjustment and others   25,644   1,400  
Net cash (used in) provided by operating activities   (29,567 ) 26,134  
       
Cash flows from investing activities      
Capital expenditures   (91,938 ) (138,615 )
Changes in advance to suppliers of property, plant and equipment   (414 ) 3,503  
Proceeds from disposal of Conduit business    -    327,631  
Loan to non-consolidated companies   (250 ) (9,006 )
Proceeds from disposal of property, plant and equipment and intangible assets   1,484   1,962  
Changes in investments in securities   84,616   (48,469 )
Net cash (used in) provided by investing activities   (6,502 ) 137,006  
       
Cash flows from financing activities      
Acquisitions of non-controlling interests    -    (18 )
Proceeds from borrowings   277,711   247,122  
Repayments of borrowings   (248,041 ) (385,609 )
Net cash provided by (used in) financing activities   29,670   (138,505 )
       
(Decrease) increase in cash and cash equivalents   (6,399 ) 24,635  
Movement in cash and cash equivalents      
At the beginning of the period   330,090   398,580  
Effect of exchange rate changes   1,050   3,526  
(Decrease) increase in cash and cash equivalents   (6,399 ) 24,635  
At March 31,   324,741   426,741  
       

Exhibit I - Alternative performance measures

EBITDA, Earnings before interest, tax, depreciation and amortization.

EBITDA provides an analysis of the operating results excluding depreciation and amortization and impairments, as they are non-cash variables which can vary substantially from company to company depending on accounting policies and the accounting value of the assets. EBITDA is an approximation to pre-tax operating cash flow and reflects cash generation before working capital variation. EBITDA is widely used by investors when evaluating businesses (multiples valuation), as well as by rating agencies and creditors to evaluate the level of debt, comparing EBITDA with net debt.

EBITDA is calculated in the following manner:

EBITDA= Operating results + Depreciation and amortization + Impairment charges/(reversals).

(all amounts in thousands of U.S. dollars) Three-month period ended March 31,
  2018 2017
Operating income 212,197 36,014
Depreciation and amortization 141,802 162,218
EBITDA 353,999 198,232

Net Cash / (Debt)

This is the net balance of cash and cash equivalents, other current investments and non-current investments less total borrowings. It provides a summary of the financial solvency and liquidity of the company. Net cash / (debt) is widely used by investors and rating agencies and creditors to assess the company's leverage, financial strength, flexibility and risks.

Net cash/ debt  is calculated in the following manner:

Net cash= Cash and cash equivalents + Other investments (Current)+ Non Current Investments - Borrowings (Current and Non-current).

(all amounts in thousands of U.S. dollars) At March 31,
  2018   2017  
Cash and bank deposits 328,675   427,619  
Other current investments 999,576   1,613,665  
Non Current Investments 234,739   316,003  
Borrowings (1,005,595 ) (708,231 )
Net cash / (debt) 557,395   1,649,056  

Free Cash Flow

Free cash flow is a measure of financial performance, calculated as operating cash flow less capital expenditures. FCF represents the cash that a company is able to generate after spending the money required to maintain or expand its asset base.

Free cash flow is calculated in the following manner:

Free cash flow= Net cash (used in) provided by operating activities - Capital expenditures.

(all amounts in thousands of U.S. dollars) Three-month period ended March 31,
  2018   2017  
Net cash (used in) provided by operating activities (29,567 ) 26,134  
Capital expenditures (91,938 ) (138,615 )
Free cash flow (121,505 ) (112,481 )
 

Giovanni Sardagna      
Tenaris
1-888-300-5432
www.tenaris.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Tenaris S.A. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum